Renal cell carcinoma

BEVACIZUMAB, SORAFENIB, SUNITINIB AND TEMSIROLIMUS

NICE Appraisal

TA178 Bevacizumab, sorafenib, sunitinib and temsirolimus for advanced and/or metastatic renal cell carcinoma

DSU Reports

Response from the DSU to comments on the extra work consultation (February 2009)

Extra work done by the DSU on the revised analyses submitted by Bayer (January 2009)

DSU addendum to the review of Roche’s request for parameter changes (January 2009)

Bevacizumab, sorafenib, sunitinib and temsirolimus for renal cell carcinoma (September 2008)

Additional analysis by assessment group and DSU (September 2008)